Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients.
Bisphosphonates
CKD
Denosumab
Osteoporosis
Renal transplant
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
30
06
2019
accepted:
15
12
2019
pubmed:
5
1
2020
medline:
19
3
2021
entrez:
5
1
2020
Statut:
ppublish
Résumé
A retrospective chart review was conducted on 85 renal transplant patients aged 19-88 years, treated with denosumab or bisphosphonate therapy. Bone densitometry measures were compared between treatment groups at baseline; at years 1, 2, and 3; and at final follow-up (average of 3.4 years). Both bisphosphonate and denosumab treatments increased lumbar spine bone density; however, the effect of denosumab was greater compared with that of bisphosphonate treatment. Denosumab treatment increased femoral neck BMD, whereas bisphosphonate treatment had a mean decrease in femoral neck BMD at final follow-up. Thus, our study provides evidence for the efficacy of denosumab treatment in renal transplant patients. Caution around hypocalcemia is warranted. We recommend more prospective studies to analyze the effects of long-term antiresorptive therapy in patients with a renal transplant. To compare the clinical effectiveness and safety between the use of denosumab and bisphosphonates on bone density and incidence of adverse events in renal transplant patients. A retrospective chart review was conducted on 85 renal transplant patients aged 19-88 years, treated with denosumab or bisphosphonate therapy. Bone densitometry measures were compared between treatment groups at baseline; years 1, 2, and 3; and at final follow-up (average of 3.4 years). Absolute change in lumbar spine and femoral neck BMD over the treatment period was 0.029 ± 0.075 g/cm Both treatments increased lumbar spine BMD; however, the effect of denosumab was greater compared with that of bisphosphonate treatment. Our study provides evidence for the efficacy of denosumab treatment in renal transplant patients. Caution around hypocalcemia is warranted. We recommend more prospective studies to analyze the effects of long-term antiresorptive therapy in patients with a renal transplant.
Identifiants
pubmed: 31900542
doi: 10.1007/s00198-019-05267-1
pii: 10.1007/s00198-019-05267-1
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Denosumab
4EQZ6YO2HI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
973-980Commentaires et corrections
Type : ErratumIn
Références
Bone. 2011 Apr 1;48(4):677-92
pubmed: 21145999
J Bone Miner Res. 2009 Jan;24(1):153-61
pubmed: 18767928
JAMA. 1999 Oct 13;282(14):1344-52
pubmed: 10527181
Intern Med. 2017 Dec 15;56(24):3271-3276
pubmed: 29021477
N Engl J Med. 2009 Aug 20;361(8):756-65
pubmed: 19671655
Kidney Int. 2009 Aug;76113:S3-8
pubmed: 26746396
Curr Osteoporos Rep. 2017 Jun;15(3):214-221
pubmed: 28474258
Transplantation. 2004 May 27;77(10):1566-71
pubmed: 15239623
Asia Pac J Clin Oncol. 2017 Aug;13(4):266-276
pubmed: 27862983
J Bone Miner Res. 2010 Aug;25(8):1886-94
pubmed: 20222106
Bone. 1992;13(3):225-8
pubmed: 1637568
J Clin Endocrinol Metab. 2011 Jun;96(6):1727-36
pubmed: 21411557
Ann Intern Med. 2008 Feb 5;148(3):197-213
pubmed: 18087050
J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70
pubmed: 27270237
J Bone Miner Res. 2005 Dec;20(12):2105-15
pubmed: 16294264
Osteoporos Sarcopenia. 2017 Mar;3(1):8-17
pubmed: 30775498
N Engl J Med. 2006 Feb 23;354(8):821-31
pubmed: 16495394
Arch Osteoporos. 2017 Dec;12(1):43
pubmed: 28425085
J Nephrol. 2017 Oct;30(5):677-687
pubmed: 28432640
Osteoporos Int. 2018 Aug;29(8):1737-1745
pubmed: 29713798
Osteoporos Int. 2016 Sep;27(9):2835-2844
pubmed: 27120345
Bone. 2011 Jul;49(1):77-81
pubmed: 21232648
Orthop Clin North Am. 2013 Apr;44(2):137-51
pubmed: 23544820
J Am Soc Nephrol. 2000 Jun;11(6):1093-9
pubmed: 10820173
Curr Rheumatol Rep. 2012 Jun;14(3):217-23
pubmed: 22350608
J Bone Metab. 2012 Nov;19(2):139-45
pubmed: 24524045
Clin J Am Soc Nephrol. 2018 Jun 7;13(6):962-969
pubmed: 29487093
Am J Med. 2013 Jan;126(1):13-20
pubmed: 23177553
Am J Transplant. 2014 Apr;14(4):943-951
pubmed: 24712332
N Engl J Med. 1996 Oct 3;335(14):1016-21
pubmed: 8793925
J Musculoskelet Neuronal Interact. 2017 Mar 1;17(1):444-449
pubmed: 28250248
J Bone Miner Res. 2007 Apr;22(4):503-8
pubmed: 17243862
J Bone Miner Res. 2012 Jul;27(7):1471-9
pubmed: 22461041
Endocr Rev. 2002 Aug;23(4):508-16
pubmed: 12202465
Kidney Int. 2008 Sep;74(6):721-31
pubmed: 18563052
Mayo Clin Proc. 2002 Oct;77(10):1044-52
pubmed: 12374248
Transplantation. 2009 Jun 27;87(12):1846-51
pubmed: 19543063
Can Fam Physician. 2014 Apr;60(4):324-33
pubmed: 24733321
Nat Rev Nephrol. 2010 Jan;6(1):32-40
pubmed: 19918255
Am J Kidney Dis. 2004 Oct;44(4):747-56
pubmed: 15384027
J Bone Miner Res. 2013 Aug;28(8):1811-20
pubmed: 23456850
Am J Kidney Dis. 2012 Oct;60(4):626-8
pubmed: 22854051
J Bone Miner Res. 2007 Dec;22(12):1832-41
pubmed: 17708711